HRP20030607A2 - Crystalline forms of atorvastatin - Google Patents

Crystalline forms of atorvastatin Download PDF

Info

Publication number
HRP20030607A2
HRP20030607A2 HR20030607A HRP20030607A HRP20030607A2 HR P20030607 A2 HRP20030607 A2 HR P20030607A2 HR 20030607 A HR20030607 A HR 20030607A HR P20030607 A HRP20030607 A HR P20030607A HR P20030607 A2 HRP20030607 A2 HR P20030607A2
Authority
HR
Croatia
Prior art keywords
intensity
calcium
atorvastatin
crystalline polymorph
characteristic
Prior art date
Application number
HR20030607A
Other languages
English (en)
Croatian (hr)
Inventor
Adriaan Van Der Schaaf Paul
Blatter Fritz
Szelagiewicz Martin
Sch�ning Kai-Uwe
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20030607A2 publication Critical patent/HRP20030607A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20030607A 2000-12-27 2001-12-19 Crystalline forms of atorvastatin HRP20030607A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00811249 2000-12-27
PCT/EP2001/015012 WO2002051804A1 (fr) 2000-12-27 2001-12-19 Formes cristallines d'atorvastatine

Publications (1)

Publication Number Publication Date
HRP20030607A2 true HRP20030607A2 (en) 2005-06-30

Family

ID=8175112

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030607A HRP20030607A2 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Country Status (23)

Country Link
US (4) US7538136B2 (fr)
EP (2) EP1345896B1 (fr)
JP (2) JP2004516311A (fr)
KR (1) KR100790766B1 (fr)
CN (1) CN1273449C (fr)
AT (1) ATE420070T1 (fr)
AU (1) AU2002224952B2 (fr)
CA (7) CA2622477A1 (fr)
CZ (1) CZ20032019A3 (fr)
DE (1) DE60137364D1 (fr)
ES (1) ES2319870T3 (fr)
HR (1) HRP20030607A2 (fr)
HU (1) HUP0302519A3 (fr)
IL (1) IL156280A0 (fr)
IS (1) IS6859A (fr)
MX (1) MXPA03005879A (fr)
NO (1) NO20032758L (fr)
NZ (1) NZ527048A (fr)
PL (1) PL365312A1 (fr)
PT (1) PT1345896E (fr)
SK (1) SK9532003A3 (fr)
WO (1) WO2002051804A1 (fr)
ZA (1) ZA200304297B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Formes cristallines d'atorvastatine
SK16002003A3 (sk) * 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
HRP20040077A2 (en) * 2001-07-30 2004-06-30 Reddys Lab Ltd Dr Crystalline forms vi and vii of atorvastatin-calcium
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CN100406436C (zh) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
CA2508871C (fr) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Forme cristalline f de sel d'hemi-calcium d'astorvastatine
EP1424324A1 (fr) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Forme cristalline F de calcium d'atorvastatine
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1761489A1 (fr) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Forme cristalline d'hemi-calcium d'atorvastatine
ATE545629T1 (de) 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2570602A1 (fr) 2004-06-11 2006-01-26 Ginkgo Biomedical Research Institute Co., Ltd. Agents regulateurs de l'activite des cellules productrices d'interferon
US8044086B2 (en) * 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (fr) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Nouvelles formes de sel hemicalcique d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (fr) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
CA2499047A1 (fr) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Methode de synthese d'un sel de semi-calcium d'atorvastatine
CZ2007772A3 (cs) * 2005-04-08 2008-02-27 EGIS GYOGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Nová krystalická polymorfní forma hemivápenaté soli atorvastatinu
CA2547216A1 (fr) 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
KR20080031487A (ko) * 2006-06-28 2008-04-08 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴의 결정형
EP2185527A2 (fr) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) * 2016-07-04 2019-10-03 ゼリア新薬工業株式会社 １，５−ベンゾジアゼピン化合物カルシウム塩の製造法
WO2025147589A1 (fr) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EP2206497A1 (fr) * 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Form polymorphe de atorvastatin calcium
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
ATE320415T1 (de) 1999-12-17 2006-04-15 Pfizer Science & Tech Ltd Verfahren zur herstellung von kristallin atorvastin kalcium
EP1332130A4 (fr) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Formes cristallines d'atorvastatine
WO2002057228A1 (fr) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatine calcique
WO2002057229A1 (fr) * 2001-01-19 2002-07-25 Biocon India Limited FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
SK16002003A3 (sk) * 2001-06-29 2004-12-01 Warner-Lambert Company Llc Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
HRP20040077A2 (en) * 2001-07-30 2004-06-30 Reddys Lab Ltd Dr Crystalline forms vi and vii of atorvastatin-calcium

Also Published As

Publication number Publication date
US7538136B2 (en) 2009-05-26
EP2000461A1 (fr) 2008-12-10
EP1345896B1 (fr) 2009-01-07
AU2002224952B2 (en) 2007-04-05
NO20032758D0 (no) 2003-06-17
CZ20032019A3 (cs) 2003-10-15
EP1345896A1 (fr) 2003-09-24
PT1345896E (pt) 2009-02-19
US20060205805A1 (en) 2006-09-14
US20040220255A1 (en) 2004-11-04
SK9532003A3 (en) 2004-04-06
IS6859A (is) 2003-06-24
JP2004516311A (ja) 2004-06-03
KR100790766B1 (ko) 2008-01-03
NZ527048A (en) 2004-12-24
DE60137364D1 (de) 2009-02-26
KR20030064880A (ko) 2003-08-02
WO2002051804A1 (fr) 2002-07-04
NO20032758L (no) 2003-06-17
JP2009221216A (ja) 2009-10-01
IL156280A0 (en) 2004-01-04
ES2319870T3 (es) 2009-05-14
PL365312A1 (en) 2004-12-27
CA2622697A1 (fr) 2002-07-04
HUP0302519A2 (hu) 2003-12-29
MXPA03005879A (es) 2003-09-10
CA2623600A1 (fr) 2002-07-04
CN1483022A (zh) 2004-03-17
HUP0302519A3 (en) 2008-10-28
US20030114686A1 (en) 2003-06-19
CA2622727A1 (fr) 2002-07-04
CA2431068A1 (fr) 2002-07-04
CA2431068C (fr) 2008-06-10
CN1273449C (zh) 2006-09-06
US20090281162A1 (en) 2009-11-12
CA2626317A1 (fr) 2002-07-04
ATE420070T1 (de) 2009-01-15
ZA200304297B (en) 2004-08-16
CA2622477A1 (fr) 2002-07-04
CA2623599A1 (fr) 2002-07-04

Similar Documents

Publication Publication Date Title
HRP20030607A2 (en) Crystalline forms of atorvastatin
AU2002224952A1 (en) Crystalline forms of atorvastatin
RU2247113C2 (ru) Способ получения аморфного аторвастатина
SK7212003A3 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
ZA200203648B (en) A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt.
EP2049479A2 (fr) Polymorphes de sels de sodium et magnesium d' atorvastatine
EP1732886B1 (fr) Polymorphes d'ester de tert-butyle d'atorvastatine et leur utilisation en tant qu'intermediaires dans la preparation d'atorvastatine
WO2007039784A2 (fr) Nouvelle forme cristalline polymorphe de sodium de fluvastatine et son procede de preparation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081216

Year of fee payment: 8

ODBI Application refused